Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SSR 128428 - sanofi-aventis

Drug Profile

SSR 128428 - sanofi-aventis

Alternative Names: SSR-128428; SSR128428E

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antithrombotics; Oligosaccharides
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis in Europe
  • 11 Feb 2009 Phase-I clinical trials in Thrombosis in Europe (unspecified route)
  • 12 Feb 2008 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top